company background image
AHEA

Apex Healthcare Berhad KLSE:AHEALTH Stock Report

Last Price

RM2.77

Market Cap

RM1.3b

7D

3.4%

1Y

-10.6%

Updated

27 Jun, 2022

Data

Company Financials +
AHEALTH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance4/6
Financial Health5/6
Dividends3/6

AHEALTH Stock Overview

Apex Healthcare Berhad, an investment holding company, engages in the development, manufacture, marketing, and distribution of pharmaceutical and healthcare products.

Rewards

Earnings are forecast to grow 5.77% per year

Earnings have grown 7.2% per year over the past 5 years

Risk Analysis

No risks detected for AHEALTH from our risk checks.

Apex Healthcare Berhad Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Apex Healthcare Berhad
Historical stock prices
Current Share PriceRM2.77
52 Week HighRM3.20
52 Week LowRM2.38
Beta0.50
1 Month Change-6.42%
3 Month Change-3.15%
1 Year Change-10.65%
3 Year Change28.24%
5 Year Change135.75%
Change since IPO814.41%

Recent News & Updates

Shareholder Returns

AHEALTHMY PharmaceuticalsMY Market
7D3.4%-3.2%-1.2%
1Y-10.6%-25.5%-8.7%

Return vs Industry: AHEALTH exceeded the MY Pharmaceuticals industry which returned -25.5% over the past year.

Return vs Market: AHEALTH underperformed the MY Market which returned -8.7% over the past year.

Price Volatility

Is AHEALTH's price volatile compared to industry and market?
AHEALTH volatility
AHEALTH Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement3.6%
Market Average Movement5.5%
10% most volatile stocks in MY Market11.5%
10% least volatile stocks in MY Market2.9%

Stable Share Price: AHEALTH is less volatile than 75% of MY stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: AHEALTH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19621,583Kirk Keehttps://www.apexhealthcare.com.my

Apex Healthcare Berhad, an investment holding company, engages in the development, manufacture, marketing, and distribution of pharmaceutical and healthcare products. It operates through three segments: Manufacturing and Marketing, Wholesale and Distribution, and Corporate. The company offers a range of products, including cough mixture and antihistamine, anti-infective, anti-diabetic, anti-hypertensive, neuromuscular agent, analgesic, dermatological, and ophthalmological products in the form of tablets, capsules, oral liquids and suspensions, creams, and sterile eye drops under the Xepa brand name.

Apex Healthcare Berhad Fundamentals Summary

How do Apex Healthcare Berhad's earnings and revenue compare to its market cap?
AHEALTH fundamental statistics
Market CapRM1.29b
Earnings (TTM)RM63.31m
Revenue (TTM)RM807.19m

20.9x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AHEALTH income statement (TTM)
RevenueRM807.19m
Cost of RevenueRM638.01m
Gross ProfitRM169.19m
Other ExpensesRM105.88m
EarningsRM63.31m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin20.96%
Net Profit Margin7.84%
Debt/Equity Ratio2.7%

How did AHEALTH perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

41%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is AHEALTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AHEALTH?

Other financial metrics that can be useful for relative valuation.

AHEALTH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.4x
Enterprise Value/EBITDA13.3x
PEG Ratio3.6x

Price to Earnings Ratio vs Peers

How does AHEALTH's PE Ratio compare to its peers?

AHEALTH PE Ratio vs Peers
The above table shows the PE ratio for AHEALTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average13.3x
DPHARMA Duopharma Biotech Berhad
15.7x7.8%RM1.1b
KOTRA Kotra Industries Berhad
9.9xn/aRM577.1m
YSPSAH Y.S.P. Southeast Asia Holding Berhad
14.9xn/aRM282.0m
RHONEMA Rhone Ma Holdings Berhad
13xn/aRM152.6m
AHEALTH Apex Healthcare Berhad
20.9x5.8%RM1.3b

Price-To-Earnings vs Peers: AHEALTH is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the peer average (13.4x).


Price to Earnings Ratio vs Industry

How does AHEALTH's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: AHEALTH is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the MY Pharmaceuticals industry average (13.9x)


Price to Earnings Ratio vs Fair Ratio

What is AHEALTH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AHEALTH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.9x
Fair PE Ratio20.6x

Price-To-Earnings vs Fair Ratio: AHEALTH is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the estimated Fair Price-To-Earnings Ratio (20.6x).


Share Price vs Fair Value

What is the Fair Price of AHEALTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AHEALTH (MYR2.77) is trading above our estimate of fair value (MYR1.3)

Significantly Below Fair Value: AHEALTH is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: AHEALTH is poor value based on its PEG Ratio (3.6x)


Discover undervalued companies

Future Growth

How is Apex Healthcare Berhad forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AHEALTH's forecast earnings growth (5.8% per year) is above the savings rate (3.6%).

Earnings vs Market: AHEALTH's earnings (5.8% per year) are forecast to grow slower than the MY market (9.9% per year).

High Growth Earnings: AHEALTH's earnings are forecast to grow, but not significantly.

Revenue vs Market: AHEALTH's revenue (5.1% per year) is forecast to grow slower than the MY market (5.2% per year).

High Growth Revenue: AHEALTH's revenue (5.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AHEALTH's Return on Equity is forecast to be low in 3 years time (12.3%).


Discover growth companies

Past Performance

How has Apex Healthcare Berhad performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


7.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AHEALTH has high quality earnings.

Growing Profit Margin: AHEALTH's current net profit margins (7.8%) are higher than last year (7.8%).


Past Earnings Growth Analysis

Earnings Trend: AHEALTH's earnings have grown by 7.2% per year over the past 5 years.

Accelerating Growth: AHEALTH's earnings growth over the past year (18.3%) exceeds its 5-year average (7.2% per year).

Earnings vs Industry: AHEALTH earnings growth over the past year (18.3%) underperformed the Pharmaceuticals industry 21.4%.


Return on Equity

High ROE: AHEALTH's Return on Equity (12.1%) is considered low.


Discover strong past performing companies

Financial Health

How is Apex Healthcare Berhad's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: AHEALTH's short term assets (MYR448.5M) exceed its short term liabilities (MYR147.4M).

Long Term Liabilities: AHEALTH's short term assets (MYR448.5M) exceed its long term liabilities (MYR20.4M).


Debt to Equity History and Analysis

Debt Level: AHEALTH has more cash than its total debt.

Reducing Debt: AHEALTH's debt to equity ratio has increased from 0% to 2.7% over the past 5 years.

Debt Coverage: AHEALTH's debt is well covered by operating cash flow (462.3%).

Interest Coverage: AHEALTH earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Apex Healthcare Berhad current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.99%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: AHEALTH's dividend (1.99%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (2.15%).

High Dividend: AHEALTH's dividend (1.99%) is low compared to the top 25% of dividend payers in the MY market (4.94%).


Stability and Growth of Payments

Stable Dividend: AHEALTH's dividend payments have been volatile in the past 10 years.

Growing Dividend: AHEALTH's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (41.2%), AHEALTH's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (70.3%), AHEALTH's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average management tenure


CEO

Kirk Kee (59 yo)

12.08yrs

Tenure

RM289,251

Compensation

Dr. Kirk Chin Kee has been the Chief Executive Officer and Chairman of Apex Healthcare Berhad since May 19, 2010 and served as its Managing Director since March 3, 2000. He has been Executive Director of A...


CEO Compensation Analysis

Compensation vs Market: Kirk's total compensation ($USD65.75K) is below average for companies of similar size in the MY market ($USD333.71K).

Compensation vs Earnings: Kirk's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AHEALTH's management team is seasoned and experienced (7.9 years average tenure).


Board Members

Experienced Board: AHEALTH's board of directors are seasoned and experienced ( 10.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Apex Healthcare Berhad's employee growth, exchange listings and data sources


Key Information

  • Name: Apex Healthcare Berhad
  • Ticker: AHEALTH
  • Exchange: KLSE
  • Founded: 1962
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: RM1.288b
  • Shares outstanding: 477.17m
  • Website: https://www.apexhealthcare.com.my

Number of Employees


Location

  • Apex Healthcare Berhad
  • 1-5, Jalan TTC 1
  • Cheng Industrial Estate
  • Malacca
  • Melaka
  • 75250
  • Malaysia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.